Study of digoxin as inhibitor of the in vivo effects of acetyl glyceryl ether phosphorylcholine (AGEPC) in mice.
Acetyl glyceryl ether phosphorylcholine (AGEPC) and the cardiac glycoside digoxin were administered intravenously through the tail vein into ether-anesthetized SWR mice (two months old). The administered doses were 0.18 nmol AGEPC/g b.w. (a lethal one) and 75 or 125 ng digoxin/b.w. Digoxin ameliorates the effects of the lethal dose of AGEPC showing maximum activity when given 5 or 10 min after AGEPC administration to female and male animals respectively. Digoxin shows also a protective action towards the effects of AGEPC and maximum activity appears when it is given 10 min before AGEPC administration. In agreement with the picture of increased survival in digoxin pretreated animals, are our findings on life prolongation of mice which finally die from AGEPC, the amelioration of the expected fall in blood platelet counts after AGEPC administration as well as the improved performance of the animals in a series of physical tests.
Kelefiotis
D
D
Biology Division, N.R.C. Demokritos, Attikis, Greece.
Lanara
E
E
Vakirtzi-Lemonias
C
C
Siafaka
A
A
Mavris
M
M
Lazanas
M
M
Demopoulos
C A
CA
D000818:Animals; D001792:Blood Platelets / Q000187:drug effects / Q000502:physiology; D004077:Digoxin / Q000494:pharmacology*; D004334:Drug Administration Schedule; D004562:Electrocardiography; D005260:Female; D006321:Heart / Q000187:drug effects / Q000502:physiology*; D008297:Male; D051379:Mice; D008815:Mice, Inbred Strains; D010972:Platelet Activating Factor / Q000037:antagonists & inhibitors*; D012016:Reference Values; D012737:Sex Factors
D010972:Platelet Activating Factor; D004077:Digoxin